Pharmaceuticals, Biotechnology and Life Sciences
– Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for…
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…
– Announces key appointments in oncology R&D and business development functions – Cash and cash equivalents of $283 million expected…
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment…
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both…
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company…
NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,…
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical…
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory…
Conference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) — Alimera Sciences,…